Pet RANKL Therapeutic Antibody Development

Creative Biolabs delivers specialized R&D services to advance therapeutic antibody programs for companion animals. With extensive expertise in veterinary biotechnology, we focus on translating cutting-edge immunology into practical treatments for canine and feline diseases. Our integrated workflow combines target discovery, antibody screening, optimization, and preclinical evaluation, ensuring each candidate is developed with scientific rigor and tailored for veterinary applications. By leveraging innovative antibody platforms and a deep understanding of pet immunology, we help partners accelerate their pipelines and bring novel treatments to market. If you are seeking a partner to explore RANKL-targeted therapies for pets, our team is ready to provide guidance and customized solutions.

Platforms in Therapeutic Antibody Discovery

We provide access to three complementary discovery platforms designed to maximize antibody diversity and clinical potential. Through these platforms. Creative Biolabs enables clients to compare strategies, validate candidates across methods, and accelerate the path from discovery to therapeutic development. If you are evaluating which discovery approach best fits your pipeline, we welcome your inquiries to discuss tailored strategies.

• Phage Display: Our proprietary libraries enable efficient screening of high-affinity binders specifically optimized for dog and cat targets. This platform accelerates early discovery by capturing a wide range of therapeutic candidates with species-relevant binding properties.
• Single-B Cell Sorting: Using advanced flow cytometry and molecular cloning, we isolate antigen-specific B cells from immunized animals. This approach generates naturally paired heavy and light chains, delivering high-quality starting material for downstream engineering and optimization of veterinary antibodies.
• Hybridoma Technology: A proven method for generating monoclonal antibodies, our hybridoma services are refined for canine and feline species. The platform supports subsequent antibody engineering and optimization tailored to veterinary immunotherapy.

Comprehensive Antibody Development Services

Our services extend beyond discovery to ensure robust therapeutic development. Each service is designed to strengthen decision-making at critical milestones. If your program requires targeted characterization or advanced preclinical evaluation, reach out to us for detailed project consultation.

Antibody Characterization

Comprehensive analysis of affinity, specificity, stability, and functionality to confirm candidate suitability.

Antibody Engineering

Optimization for improved potency, reduced immunogenicity, and enhanced developability in canine and feline systems.

Preclinical Evaluation

Rigorous in vitro and in vivo studies to establish pharmacodynamics, safety, and efficacy in relevant models.

Antibody Development

End-to-end process support from lead selection to production-ready candidates, including scalable expression systems and quality control.

Discover How We Can Help - Request a Consultation

Why Focus on RANKL?

RANKL (Receptor Activator of Nuclear factor-kappa B Ligand), or receptor activator of nuclear factor kappa-B ligand, is a critical regulator of bone metabolism and immune function. Excessive RANKL activity contributes to osteoclast-mediated bone resorption, leading to disorders such as osteoporosis-like conditions, bone loss associated with arthritis, periodontal disease, and certain tumor-induced bone complications. In dogs, RANKL-driven pathways are implicated in osteoarthritis and oral cancers, while in cats, periodontal disease is particularly relevant. Because of its central role across both species, targeting RANKL provides a promising therapeutic avenue to address painful, degenerative, or inflammatory conditions that compromise quality of life. Veterinary RANKL inhibition may therefore help preserve skeletal integrity, reduce inflammation, and mitigate disease progression.

Mechanism of Action

The mechanism of action for RANKL-targeting antibodies involves binding to the ligand and blocking its interaction with the receptor RANK on osteoclast precursors. This inhibition prevents osteoclast differentiation and activity, thereby reducing bone resorption and restoring balance in bone remodeling. Beyond bone health, RANKL antibodies can indirectly modulate inflammatory cascades and tumor microenvironments where the RANK/RANKL/OPG axis is dysregulated. By controlling these pathways, therapeutic antibodies hold the potential to not only alleviate clinical symptoms but also slow underlying disease processes in companion animals.

Fig 1. RANKL expression in cytologic preparations of dog patient samples.¹

Our Advantages

• Our team combines species-specific expertise, proprietary discovery libraries, and integrated downstream services that reduce development risks.
• We maintain rigorous quality standards aligned with both research and translational needs, ensuring reproducibility and scalability.
• Our flexible project structures allow clients to engage at any stage,whether for initial discovery, focused engineering, or comprehensive development.
• By tailoring workflows to each client's therapeutic goals, we provide efficiency, precision, and high-value outcomes.

Partner with Creative Biolabs

Advancing RANKL-targeted therapies for pets requires a partner with both scientific depth and veterinary focus. Creative Biolabs is committed to helping innovators bring effective treatments to market for the benefit of companion animals worldwide. From discovery to preclinical validation, our comprehensive services are designed to streamline development and maximize therapeutic potential. We invite you to partner with us and take the next step in pioneering veterinary antibody therapeutics. Contact our team today to begin a conversation about your RANKL-focused project or broader pipeline needs.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Barger, Anne M et al. "Expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in neoplasms of dogs and cats." Journal of veterinary internal medicine vol. 21,1 (2007): 133-40. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1111/j.1939-1676.2007.tb02939.x